<DOC>
	<DOC>NCT02810301</DOC>
	<brief_summary>Study to demonstrate the efficacy of Probiotic ES1 in alleviating symptoms of gluten sensitivity in non-celiac gluten sensitive subjects exposed to a small, fixed amount of gluten.</brief_summary>
	<brief_title>Efficacy of Probiotic ES1 for the Treatment of Non-Celiac Gluten Sensitivity</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled study. Sixty non-celiac gluten sensitive subjects will be randomized into one of two groups; Probiotic ES1 or placebo. For the duration of the study, subjects must adhere to a gluten-free diet, apart from a scheduled fixed gluten exposure of two slices of bread once daily. Subjects will be required to take 1 capsule before and after consuming the two slices of bread and score the severity of their symptoms in a diary provided for the duration of the study (7 days).</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Sulfalene</mesh_term>
	<criteria>Age: 1865 Male or nonpregnant, nonlactating females. Documented or selfdiagnosed gluten sensitivity that is wellcontrolled. Negative celiac serology to eliminate Celiac Disease at screening. Written informed consent prior to any screening procedure. Ability and willingness to comply with study requirements. Adherence to a glutenfree diet during period of the study and 1 week prior to the first dose. BMI &lt; 35 kg/m2. History of diagnosis of Celiac Disease. Positive pregnancy test at screening. Positive HIV, Hepatitis, or Tuberculosis infection. History of substance abuse within last 5 years. Alcohol consumption of &gt; 2 standard drink equivalents per day. Recent myocardial infarction within past 3 months, recent stroke within past 12 months, recent abdominal surgery within past 12 months, history of any malignancies and/or active treatment for a psychiatric disorder. Use of systemic biologics within 6 months of the study. Use of oral probiotics within 2 weeks of the study. Use of NSAIDS or aspirin within 7 days of the study. Use of immunosuppressants within 30 days of the study. Family history (first degree relative) of Celiac Disease. Received an investigational product within 1 month of study. History of digestive enzyme deficiencies. History of severe reactions to low doses of gluten/accidental exposure to gluten. History of wheat allergy (positive reactions to the skinprick test or the IgE blood test). History of lactose, milk protein and/or FODMAP allergies. Subjects who have an immunecompromised condition.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>gluten</keyword>
	<keyword>non-celiac</keyword>
	<keyword>gluten sensitivity</keyword>
</DOC>